Targeted therapies are also limited as SCLC is a highly heterogenous disease and most of the known associated modulators (ASCL1, NEUROD1, POU2F3, and PLCG2) are currently undruggable[48]. This evidence concerns the gene POU2F3 and small cell lung carcinoma.